Table 1.
Baseline characteristics.
| Total cohort (n = 166) |
Intention for early low-dose DLI (n = 62) |
No intention for early low-dose DLI (n = 104) |
|
|---|---|---|---|
| Age at alloSCT (years) | |||
| median (range) | 63 (28–78) | 64 (31-78) | 63 (28-73) |
| Disease | |||
| AML | 133 (80%) | 46 (74%) | 87 (84%) |
| ALL | 17 (10%) | 10 (16%) | 7 (7%) |
| MDS | 16 (10%) | 6 (10%) | 10 (10%) |
| Nonmyeloablative conditioning | |||
| Flu/Bu | 150 (90%)* | 46 (74%) | 104 (100%)* |
| Flu/Bu/Ara-C/Amsa (FLAMSA) | 16 (10%) | 16 (26%) | 0 |
| Donor | |||
| RD, 10/10 HLA matched | 57 (34%) | 20 (32%) | 37 (36%) |
| UD, 10/10 HLA matched | 101 (61%) | 39 (63%) | 62 (60%) |
| UD, 9/10 HLA matched | 8 (5%) | 3 (5%) | 5 (5%) |
| Graft source | |||
| G-CSF mobilized PBSC | 165 (99%) | 62 (100%) | 103 (99%) |
| BM | 1 (1%) | 0 | 1 (1%) |
| CMV serostatus patient/donor | |||
| +/+ | 79 (48%) | 32 (52%) | 47 (45%) |
| +/- | 25 (15%) | 8 (13%) | 17 (16%) |
| -/+ | 11 (7%) | 4 (6%) | 7 (7%) |
| -/- | 51 (31%) | 18 (29%) | 33 (32%) |
| Main reason for intention for early low-dose DLI | |||
| FLAMSA regimen | - | 16 (26%) | - |
| MRD+ at time of alloSCT | – | 14 (23%) | – |
| AML/MDS: EVI1 overexpression | - | 9 (15%) | - |
| AML: monosomal karyotype | – | 8 (13%) | – |
| AML: ASXL mutation, only one remission induction course, or persisting underlying disease |
- | 4 (6%) | - |
| ALL: t(9;22) | – | 4 (6%) | – |
| ALL: hypodiploidy, no CR1, or t(4;11) |
- | 4 (6%) | - |
| Therapy-related AML | – | 2 (3%) | – |
| AML: progression before alloSCT | - | 1 (2%) | - |
*One patient had not received a second consolidation course before transplant and received 2 days cyclophosphamide 750 mg/m2 intravenously additionally to the conditioning regimen.
Intention for early low-dose DLI is based on the anticipated high risk of relapse after alloSCT. DLI, donor lymphocyte infusion; alloSCT, allogeneic stem cell transplantation; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; Flu, fludarabine; Bu, busulfan; Ara-C, cytarabine; Amsa, amsacrine; RD, related donor; UD, unrelated donor; G-CSF, granulocyte-colony stimulation factor; PBSC, peripheral blood stem cells; BM, bone marrow.